| Overview |
| bsm-61939r-100ul |
| METAP2 Recombinant Monoclonal Antibody |
| WB, FCM, IHC-P, IHC-F, IF(ICC), IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human METAP2 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Shipped at 4°. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 10988 |
| P50579 |
| Cytoplasm |
| Amp2; MAP2; Metap2; MNPEP; p67; p67eIF2. |
| Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(ICC) |
1:50-200 |
| IF |
|
Powered by Bioz